Efficacy and Safety of CETP Inhibitors in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Román Rodríguez Milán, Magda S Jiménez Castellanos, Adrián D Doníz Viveros et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of cholesteryl ester transfer protein (CETP) inhibitors in 62,565 patients with atherosclerotic cardiovascular disease. The analysis found that CETP inhibitors did not significantly reduce major adverse cardiovascular events compared to placebo, with a risk ratio for death from coronary heart disease of 0.91 (95% CI, 0.82 to 1.01).
Key findings
- CETP inhibitors did not significantly reduce death from coronary heart disease (RR: 0.91; 95% CI, 0.82 to 1.01).
- No significant reduction in nonfatal myocardial infarction was observed (RR: 0.94; 95% CI, 0.87-1.02).
- CETP inhibitors significantly increased HDL-C by 130.82% (95% CI, 121.49-140.15).
- No excess risk of adverse events was noted (RR: 1.00; 95% CI, 0.99-1.02).
Why it matters
The findings highlight that while CETP inhibitors can improve lipid profiles, they do not translate into reduced cardiovascular events. This raises important considerations for clinicians regarding the reliance on lipid-modifying therapies as a strategy for cardiovascular risk reduction.